常山药业(300255.SZ)：艾本那肽尚未完成审评

Group 1 - The core point of the article is that Changshan Pharmaceutical (300255.SZ) has stated on its investor interaction platform that the review of Aibennapeptide has not yet been completed [1] Group 2 - The company is currently awaiting the completion of the review process for Aibennapeptide, indicating a potential delay in product development or market entry [1]